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Increased plasma total homocysteine (tHcy) levels have been shown to be a risk factor for coronary artery disease (CAD). The
common methylenetetrahydrofolate reductase C677T (MTHFR C677T) polymorphism has been reported to be a strong predic-
tor of mild hyperhomocysteinaemia (HHcy). We assessed whether this mutation was associated with increased risk of CAD and
plasma levels of tHcy. We also evaluated interactions between this polymorphism, mild elevated tHcy levels and conventional risk
factors of CAD. Method. Using PCR-RFLP analysis, we studied the frequency of the C677T genotypes and its eﬀect on CAD and
on tHcy concentrations in 400 subjects without and with CAD angiographically conﬁrmed. There were 210 subjects with CAD
and 190 subjects without CAD. Results. The frequencies of the C677T genotypes were 53% (59.5% in controls versus 48.1% in
cases), 34.8% (32.1 in controls versus 37.1 in cases), and 11.8% (8.4% in controls versus 14.8% in cases), respectively, for 677CC,
677CT, and 677TT. The genotype frequencies were signiﬁcantly diﬀerent between case and control groups (P<. 05). The 677T
allele enhances the risk of CAD associated to HHcy (P<. 01). In multivariate analysis models, MTHFR C677T polymorphism
eﬀect on CAD was masked by other risk factors. HHcy was only and independently inﬂuenced by MTHFR polymorphism and
smoking habits, and it is a strong predictor of CAD independently of conventional risk factors. Conclusion. Our data suggest that
HHcyisstronglyand independentlyassociated toCADriskincrease; andMTHFRC677Tpolymorphismandsmokinghabitswere
the main predictors of tHcy levels. The CAD risk increase is mainly associated with mild HHcy in 677TT, whereas in 677CT and
677CC it is mainly associated with the conventional risk factors.
Copyright © 2007 Nawal Bennouar et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Atherosclerosis is a common disease primarily aﬀecting large
arteries, which begins in childhood and progresses with age.
It is the principal cause of heart attack, stroke, and gangrene
of the extremities [1]. Several pathophysiologic mechanisms,
includingtheinﬂammatoryresponse,immuneresponse,cel-
lular growth and proliferation, lipoprotein metabolism and
coagulation, each of which are regulated by numerous gene
products, can contribute to atherosclerosis either individu-
allyorinconcert.Epidemiologicstudieshaverevealedseveral
important environmental and genetic risk factors associated
with atherosclerosis [2].
One of the candidate genes for the development of
atherosclerosisregardlessoflocalizationismethylenetetrahy-
drofolate reductase (MTHFR; EC 1.5.1.20). MTHFR is a
regulatory enzyme of the homocysteine (Hcy) metabolism,
and is also necessary in the metabolism of tetrahydrofolate,2 Journal of Biomedicine and Biotechnology
as well as in the synthesis of purine, DNA, and RNA. El-
evated plasma total homocysteine (tHcy) concentration is
now widely accepted as a major independent risk factor for
cerebrovascular,peripheralvasculardiseaseandmayexplain,
at least in part, the occurrence of coronary artery disease
(CAD) in patients who do not have dyslipidemia, hyperten-
sion, and other conventional risk factors [3, 4].
Hcy is a sulphur-containing amino acid, formed by de-
methylation of the essential amino acid methionine. It can
beeitherdegraded bytranssulfuration,involving thevitamin
B6-dependant enzyme cystathionineβ-synthase,orremethy-
lated to methionine, involving the cobalamine (vitamin B12-
dependant enzyme) methionine synthase. Elevations of tHcy
might result from nutritional deﬁciencies, including folate,
pyridoxalphosphate(vitaminB6),andmethylcobalamin(vi-
tamin B12), or from genetically determined abnormalities of
Hcy metabolism (e.g., MTHFR), or a combination of these
[5, 6].
MTHFR is an enzyme that reduces 5,10-methylenetet-
rahydrofolate to 5-methylenetetrahydrofolate, the main cir-
culatingformoffolateandthemethyldonorfortheremethy-
lation of Hcy to methionine. The MTHFR gene has been
mapped to the chromosomal region 1p36.3. A thermolabile
form of MTHFR has been identiﬁed [7, 8]a n df o u n dt ob e
caused by a missense mutation in its encoding gene, with the
cytidine residue at nucleotide position 677 being replaced by
thymidine (MTHFR C677T), resulting in the substitution of
valine for alanine in the enzyme. The homozygous 677TT
genotype of this mutation has been found to specify a vari-
ant enzyme with reduced activity and to be associated with
elevated tHcy levels, particularly in the setting of low folate
levels, as compared to the wild-type (677CC) and heterozy-
gous (677CT) genotypes. Also, data have shown that the fre-
quency of the mutation varies among diﬀerent populations
[9, 10]. These considerations have raised the possibility that
the relatively common C677T mutation in MTHFR might
be an important genetic risk factor for cardiovascular disease
through its eﬀects on homocysteine metabolism [11, 12].
The aim of this study was to investigate the frequency of
MTHFR C677T mutation and its association to CAD and to
fastingplasmatHcyconcentrationsinMoroccanpopulation.
We also evaluated interactions between mild elevated tHcy
levels, MTHFR C677T polymorphism, and conventional risk
factors of CAD.
2. MATERIALS AND METHODS
2.1. Subjects
The study sample consisted of individuals undergoing coro-
nary angiography because of either symptoms of suspected
CAD or unrelated conditions requiring angiographic evalu-
ation (e.g., cardiomyopathy, valvular disease). Patients were
designated as having CAD if they had ≥50% stenosis of at
leastonecoronaryartery,andhavingnoCADif<10%steno-
sis was present in all major vessels.
The protocol was ethicallyapproved bythe ReviewBoard
of the National League of Cardiology, Rabat, Morocco. The
study consisted of 400 unrelated individuals (age mean =
50 ± 10) in whom coronary angiography was clinically indi-
cated(218men,182women).Thegroupofcaseswasformed
by 210 (52.5%) patients with angiographically conﬁrmed
CAD. The group of controls included 190 (47.5%) subjects
with normal coronary angiograms. Angiograms were an-
alyzed by cardiologists blinded to risk factors and genetic
study. Patients with an acute illness, such as myocardial in-
farction or coronary artery bypass graft surgery occurring
three months prior the study, or with a chronic disease, such
as chronic renal, hepatic or thyroid failure, were excluded
of the protocol. None of the subjects took vitamin supple-
ments.
2.2. Deﬁnitionofconventionalcardiovascular
riskfactors
Arterial hypertension was deﬁned in the presence of active
treatment with antihypertensive agents or otherwise as sys-
tolic blood pressure of ≥140mmHg and/or diastolic blood
pressure of ≥90mmHg on at least two separate occasions.
Hypercholesterolemia was deﬁned as a total cholesterol value
of ≥5.70mmol/L. Smokers were deﬁned as those currently
smoking any tobacco. Patients were considered to have di-
abetes mellitus if they were receiving active treatment with
insulin or oral hypoglycemic agents, or if fasting glucose in
the serum was ≥126mg/dL. Dyslipidemia was deﬁned as
triglycerides (TG) value of ≥1.50mmol/L or LDL choles-
terol (LDLc) value of ≥3.92mmol/L. The weight and height
were measured and the body mass index (BMI) was obtained
f r o mt h er a t i oo fw e i g h t( K g )t oh e i g h ts q u a r e d( m 2). Sub-
jects were considered substantially obese when the BMI was
>30Kg/m2.
2.3. Biochemicalanalyses
Twelve hour fasting venous blood samples were obtained
from all subjects at the day of the coronary angiography. Ve-
nous blood was collected into heparinized tubes and imme-
diately centrifuged at 1.550g for 10 minutes. Total serum
cholesterol, HDL cholesterol, and triglycerides were mea-
sured by enzymatic methods on a Hitachi analyzer using
standard kits (Roche Diagnostics). LDL cholesterol was cal-
culated with the Friedewald formula in subjects with triglyc-
erides levels below 4.40mmol/L.
2.4. Determinationofhomocysteine
Plasma total homocysteine was determined by immunoas-
say (Axis Biochemicals, Oslo, Norway). The assay method
was based on an enzymatic conversion of homocysteine to
S-adenosyl-L-homocysteine, followed by quantiﬁcation of S-
adenosyl-L-homocysteine by an enzyme-linked immunoas-
say [13]. The coeﬃcients of variation within and between
days for the assays were 5% or less. Cross reactivity with glu-
tathione, L-cysteine, adenosine, L-cystathionine was below
0.1%.Plasmahomocysteinewasrecordedinunitsof μmol/L.Nawal Bennouar et al. 3
2.5. Geneticanalysis
DNAwasextractedfromwhitecellsoffreshorfrozenperiph-
eral blood by phenol-chloroforme-isoamylalcool method.
The region surrounding the 677 MTHFR mutation site (a
223bp fragment) was polymerase chain reaction-ampliﬁed,
using the following primers (MTHFR 618A: 5 -AGCTTTG-
AGGCTGACCTGAAG-3  and MTHFR 14-5B: 5 -AGGAC-
GGTGCGGTGAGAGTG-3 ) (Oligo Express) [12]. PCR am-
pliﬁcation reactions were performed with 300ng of genomic
DNA in PCR buﬀer containing 1.5mM MgCl2, 200μM
dNTPs, 0.1μMo fe a c hp r i m e r ,a n d1 UTaq polymerase (Ap-
plied Biosystems). The reaction mixture (20μL) was dena-
tured at 94◦C for 1 minute, annealed at 58◦C for 15 seconds
and extended at 72◦C for 30 seconds for a total of 34 cy-
cles.SincethepolymorphismcreatesaHinfIrecognitionsite,
5μL of the PCR product was then digested with 5U HinfI,
2μL 10X reaction NE buﬀer 2 (New England, Biolabs) and
12.5μL of water at 37◦C for 3 hours. The digestion prod-
uct was electrophoresed on a 2.5% agarose gel. Restriction
fragments were stained with ethidium bromide. The wild-
type allele (677C) corresponds to the presence of one band
of 223bp, and the mutant allele (677T) corresponds to the
presenceoftwobandsof175bpand48bp.Theheterozygous
genotype (CT) corresponds to the presence of three bands of
223, 175, and 48bp.
2.6. Statisticalanalysis
Normal data distributions were assessed with the Kolmog-
orov-Smirnov test. Skewed variables were naturally log-
transformed to normalize the distribution before any statis-
tical analysis. The Student’s t-test and one-way ANOVA pro-
cedures were used for mean comparison between groups.
Hardy-Weinberg equilibrium was assessed by Chi-square
test, which was equally used for the comparison of cate-
gorical variables between two groups. The comparison be-
tweenthreegroupswasassuredbytheKruskal-Wallistestand
the adequate post hoc multiple comparisons. Model selec-
tion log-linear analysis based on backward elimination was
used for highly correlated variables identiﬁcation, and the
discriminant analysis with stepwise method was computed
for identifying variables that have signiﬁcant eﬀects on CAD
and on HHcy. On the basis of the previous statistical anal-
ysis, logistic regression model with backward likelihood ra-
tio method was used to compute odds ratio (ORs) and their
95% conﬁdence interval (95% CI). All statistical analysis was
performed with SPSS for windows (Release 7.5.1; Standard
version). All tests were two-tailed and P-value of <.05 was
deemed signiﬁcant.
3. RESULTS
Thedemographiccharacteristicsofthestudypopulationand
the main risk factors are presented in Table 1.A se x p e c t e d ,
patients with CAD had more adverse atherosclerosis pro-
ﬁle than controls. The mean age, frequency of occurrence
in men, hypertension, smoking, diabetes, dyslipidemia, and
obesity were signiﬁcantly higher in cases than in controls
(P<. 05).TheriskofCADweresigniﬁcantlyincreasedbythe
presence of conventional risk factors (all 95% CI not contain
the value of 0), and varying from ≈ 1.5 fold for male com-
pared to female (OR = 1.60, 95% CI: 1.07–2.38, P<. 05)
to ≈ 3 fold for smoking habits compared to no smoking
(OR = 2.97, 95% CI: 1.84–4.78, P<. 001).
Independently of CAD, no signiﬁcant diﬀerence was
found between men and women for MTHFR C677T geno-
type frequencies (P = .880). In women, the genotype fre-
quencies were 53.3% (21.4% in cases and 31.9% in controls),
35.7% (17.0% in cases and 18.7% in controls), and 11.0%
(7.7% in cases and 3.3% in controls) for 677CC, 677CT, and
677TT, respectively. In men, the genotype frequencies were
53.7% (28.4% in case and 25.2% in controls), 33.9% (21.6%
in cases and 12.4% in controls), and 12.4% (7.8% in cases
and 4.6% in controls) for 677CC, 677CT, and 677TT, respec-
tively. MTHFR C677T polymorphism and CAD were signif-
icantly independent in men (P = .302); but in women, the
association was at the limit of the signiﬁcance (P = .049).
MTHFR genotype and allele frequencies are shown in
Table 2. For the overall population, the prevalence of 677CC,
677CT, and 677TT genotypes were 53.5%, 34.8%, and
11.8%, respectively. The mutant homozygous, 677TT, was
recordedin8.4%ofcontrolsand14.8%ofCADpatients.The
wild-type genotype, 677CC, was found in 59.5% of controls
and 48.1% of CAD subjects. The mutant allele frequency
was 33.3% for CAD patients and 24.5% for subjects without
CAD. The diﬀerence between controls and CAD patients was
statistically signiﬁcant for MTHFR genotype and allele fre-
quencies (P<. 05). Taking the wild-type genotype as a refer-
ence, the mutant genotype increases the risk of CAD by ≈ 2
fold(OR = 2.17,95%CI:1.12–4.20,P<. 05),whiletheCAD
risk increase associated to the mutant allele (677T) was ≈ 1.5
fold compared to the wild-type allele 677C (OR = 1.54, 95%
CI: 1.11–1.84, P<. 01).
Subjects with CAD had signiﬁcantly (P<. 001) higher
tHcy levels (mean ±SD = 14.9 ± 3.1μmol/L) than con-
trols (11.3 ± 3.1μmol/L). Using 15μmol/L as the cut-
oﬀ point to classify mild hyperhomocysteinaemia (HHcy),
49.5% of CAD patients (49.2% men, 50.0% women) and
21.1% of controls (27.2% men, 15.3% women) had HHcy
(Table 2). Mild HHcy was signiﬁcantly associated to CAD
(P<. 001) in men and women separately. In all subjects,
CAD was signiﬁcantly associated to HHcy, with a risk in-
crease of about 4 fold compared to non-HHcy (OR = 3.68,
95% CI: 2.37–5.72, P<. 001). tHcy levels were positively
and signiﬁcantly associated to MTHFR gene polymorphism
(Spearman’s rho = 0.38, P<. 001). This relationship was ob-
served in case (Spearman’s rho = 0.44, P<. 001) and control
(Spearman’s rho = 0.32, P<. 01) groups. Based on the post
hoc multiple comparisonappropriate forequalvariancesnot
assumed, there is a graded and signiﬁcant (P<. 01) increase
in tHcy levels from 677CC to 677TT genotypes of MTHFR
gene in both cases and controls groups.
The frequencies of the simultaneous presence of CAD
and HHcy were 16.4%, 30.2%, and 57.4% in 677CC,
677CT, and 677TT genotypes, respectively (see Table 2).4 Journal of Biomedicine and Biotechnology
Table 1: Characteristics of the studied population and OR of CAD associated to traditional risk factors. P1 is a comparison between case
and control groups of mean age (ANOVA), and traditional risk factors (chi-square test). OR: odds ratio; 95% CI: 95% conﬁdence interval.
Total population Control Case P1 OR (95% CI)
Number of subjects 400 190 210 — —
Age, year — — — 0.000 —
Mean ± SD 49.9 ±9.84 7 .3 ±9.45 2 .3 ±9.6— —
Sex, n (%) — — — 0.020 —
Women 182 (45.5) 98 (51.6) 84 (40.0) — 1.00
Men 218 (54.5) 92 (48.4) 126 (60.0) — 1.60 (1.07–2.38)
Smoking, n (%) — — — 0.000 —
No 292 (73.0) 159 (83.7) 133 (63.3) — 1.00
Yes 108 (27.0) 31 (16.3) 77 (36.7) — 2.97 (1.84–4.78)
Hypertension, n (%) — — — 0.003 —
No 254 (63.5) 135 (71.1) 119 (56.7) — 1.00
Yes 146 (36.5) 55 (28.9) 91 (43.3) — 1.88 (1.24–2.84)
Diabetes, n (%) — — — 0.016 —
No 307 (76.8) 156 (82.1) 151 (71.9) — 1.00
Yes 93 (23.3) 34 (17.9) 59 (28.1) — 1.79 (1.11–2.89)
Obesity, n (%) — — — 0.029 —
No 292 (73.0) 148 (77.9) 144 (68.6) — 1.00
Yes 108 (27.0) 42 (22.1) 66 (31.4) — 1.62 (1.03–2.54)
Dyslipidemia, n (%) — — — 0.018 —
No 296 (74.0) 151 (79.5) 145 (69.0) — 1.00
Yes 104 (26.0) 39 (20.5) 65 (31.0) — 1.74 (1.10–2.74)
Discriminant analysis and model selection log-linear anal-
ysis were computed prior to the logistic regression analy-
sis based on the backward likelihood ratio method. The ﬁ-
nal model shows that HHcy is mainly and only signiﬁcantly
(P<. 01) aﬀected by the MTHFR polymorphism and smok-
ing habits, and their combined eﬀects were not signiﬁcant
(see Table 3). The mutant genotype had the more adverse ef-
fect (OR = 11.72, 95% CI: 4.91–27.96, P<. 001) than smok-
ing habits (OR = 6.92, 95% CI: 3.50–13.70, P<. 001).
As expected, traditional risk factor frequencies were
higherincasesthancontrols,withexceptionfordyslipidemia
and obesity in the 677TT genotypes. In cases subjects, all
conventional risk factor frequencies were lower in 677TT
genotype than in the remainders (see Table 4). Those dif-
ferences lead to think that conventional risk factors do not
have the same eﬀect on CAD according to MTHFR geno-
types. In fact, in subjects with the wild-type genotype, the
CAD risk increase was signiﬁcantly associated to smoking
habits, obesity, Dyslipidemia, and hypertension. In heterozy-
gous individuals, the risk increase was more likely associated
to smoking habits and hypertension; while the HHcy was the
sole factor that signiﬁcantly increases the risk of CAD in sub-
jects with the mutant genotype. In addition, it is important
to note that HHcy was associated to a signiﬁcant and graded
CAD risk increase from ≈ 2.5 fold in subjects with 677CC
genotype (OR = 2.47, 95% CI: 1.31–4.65, P<. 01) to ≈ 9
fold in individuals with 677TT genotype (OR = 8.68, 95%
CI: 2.05–36.69, P<. 01). In consequence, it appears that
the 677T allele multiplies by 2 the risk of CAD associated to
HHcy (see Table 5).
On the basis of the results from model selection log-
linear analysis and discriminant analysis procedures, logis-
tic regression model based on backward likelihood method
was used to compute the OR of CAD associated to the stud-
ied parameters (see Table 6). Dyslipidemia, smoking habits,
hypertension, and diabetes, as well as HHcy, were indepen-
dent risk factors for CAD. The MTHFR polymorphism eﬀect
was masked. Therefore, MTHFR polymorphism and HHcy
interactive eﬀect were found to be a strong predictor of CAD
risk(P<. 01).Thenegativeinteractiveeﬀectsbetweensmok-
ing habits and mutant genotype, as well as between Dyslipi-
demia and HHcy, should be more likely the consequence
of the small observed frequencies of smokers with 677TT
genotype and the lowest frequency of HHcy among sub-
jects with Dyslipidemia, rather than an eventual protective
eﬀect.
4. DISCUSSION
In accordance with a previous study (see [14]), the present
reportconﬁrmsthatCADisstronglyandsigniﬁcantlyassoci-
ated to HHcy in Moroccan population. This is in agreement
with the meta-analysis by Christen et al. [15], in which 43
studies were analyzed. In another meta-analysis, Boushey et
al. [4] evaluated 27 studies and showed that Hcy is an inde-
pendent and gradual risk factor for CAD. The ORs for CAD
ranged from 1.6 for men to 1.8 for women, for each tHcy
level elevation of 5μM. The increase in coronary risk result-
ing from this increase is similar to an increase of 20mg/dL
in total cholesterol levels. The authors considered that 10%Nawal Bennouar et al. 5
Table 2: Hyperhomocysteinaemia and MTHFR polymorphism distributions according to CAD, and HHcy distribution according to
MTHFR polymorphism and CAD. P1 is an MTHFR polymorphism and HHcy comparison (chi-square test) and Hcy comparison (ANOVA
and median tests) between cases and controls. P2 is the signiﬁcant value of the hypothesis testing that the OR of CAD associated to MTHFR
polymorphism and HHcy is 1. P3 is a tHcy comparison between genotypes in cases and controls separately (Kruskal-Wallis test). P4 is a tHcy
comparison between genotypes in total population (Kruskal-Wallis test).
Total population Control Case P1 OR (95% CI) P2
Number of subjects 400 190 210 — — —
MTHFR C677T —— — —— —
Genotype, n (%) — — — 0.038 — —
677CC 214 (53.5) 113 (59.5) 101 (48.1) — 1.00 —
677CT 139 (34.8) 61 (32.1) 78 (37.1) — 1.43 (0.93–2.20) 0.102
677TT 47 (11.8) 16 (8.4) 31 (14.8) — 2.17 (1.12–4.20) 0.022
Allele, n (%) — — — 0.006 — —
677C 567 (70.9) 287 (75.5) 280 (66.7) — 1.00 —
677T 233 (29.1) 93 (24.5) 140 (33.3) — 1.54 (1.11–1.84) 0.007
tHcy, μmol/L —— — —— —
Mean ±SD 13.1 ±3.61 1 .3 ±3.11 4 .8 ±3.1 0.000 — —
Median 13.8 11.1 14.9 0.000 — —
HHcy, n (%) — — — 0.000 — —
No 256 (64.0) 150 (78.9) 106 (50.5) — 1.00 —
Yes 144 (36.0) 40 (21.1) 104 (49.5) — 3.68 (2.37–5.72) 0.000
MTHFR polymorphism
Total population 677CC 677CT 677TT P3 P4
Number of subjects 400 214 139 47 — —
tHcy, μmol/L — — — — — 0.000
Case 14.9 ±3.11 3 .7 ±2.31 5 .0 ±2.41 8 .3 ±4.0 0.000 —
Control 11.3 ±3.11 0 .5 ±3.01 1 .9 ±2.91 4 .1 ±2.2 0.000 —
HHcy, n (%) — — — — — 0.007
Case 104 (26.0) 35 (16.4) 42 (30.2) 27 (57.4) 0.000 —
Control 40 (10.0) 18 (8.4) 14 (10.1) 8 (17.0) 0.007 —
Table 3: Logistic regression model (with backward likelihood ratio method) built with HHcy as a dependent variable and all other risk
factors as predictors variables. B: logistic regression coeﬃcient; SE: standard error; Df: degree of freedom; Sig.: signiﬁcant level; OR: odds
ratio; 95% CI: 95% conﬁdence interval of the OR.
Variable B SE Wald Df Sig. OR 95% CI for OR
Lower Upper
MTHFR C677T — — 31.62 2 0.000 — — —
MTHFR 677CT 0.88 0.31 8.07 1 0.005 2.40 1.31 4.40
MTHFR 677TT 2.46 0.44 30.79 1 0.000 11.72 4.91 27.96
Smoking habits 1.93 0.35 30.83 1 0.000 6.92 3.50 13.70
MTHFR C677T∗ smoking habits — — 2.28 2 0.320 — — —
MTHFR 677CT∗ smoking habits −0.40 0.54 0.54 1 0.461 0.67 0.23 1.94
MTHFR 677TT∗ smoking habits −1.21 0.82 2.16 1 0.142 0.30 0.06 1.50
Constant −1.72 0.22 60.19 1 0.000 — — —
∗Indicates the interactive eﬀects between variables.
of the risk of the general population for the development of
CAD can be attributed to Hcy.
The homocysteine hypothesis of atherosclerosis was
largely based on the clinical and pathological observations
in patients with homocystinuria, a metabolic disorder char-
acterized by markedly increased levels of homocysteine [16].
Biologic support of the theory was derived from experimen-
tal studies in which homocysteine concentrations far ex-
ceeded the levels encountered, even under the most severe
pathological conditions, putting doubt on pathophysiologi-
cal relevance in the clinical setting [17]. The strongest sup-
port for a possible causal link between homocysteine levels
and atherosclerosis came from retrospective, cross-sectional,
or case-control studies.6 Journal of Biomedicine and Biotechnology
Table 4: Traditional risk factors distribution according to MTHFR polymorphism and CAD. 677CC, 677CT, and 667TT are the wild-type,
the heterozygous, and the mutant genotypes. Comparison of traditional risk factors between MTHFR genotypes (chi-square test), in cases
and controls separately (P1) and in all subjects (P2).
Total population MTHFR polymorphism P1 P2
677CC 677CT 677TT
Number of subjects 400 214 139 47 ——
Male gender, n (%) — ——— — 0.302
Case 126 (31.5) 62 (29.0) 47 (33.8) 17 (36.2) 0.81 —
Control 92 (23.0) 55 (25.7) 27 (19.4) 10 (21.3) 0.43 —
Smoking yes, n (%) — ——— — 0.023
Case 77 (19.3) 41 (19.2) 29 (20.9) 7 (14.9) 0.19 —
Control 31 (7.8) 15 (7.0) 7 (5.0) 9 (19.1) 0.000 —
Hypertension yes, n (%) — ——— — 0.317
Case 91 (22.8) 51 (23.8) 30 (21.6) 10 (21.3) 0.11 —
Control 55 (13.8) 39 (18.2) 13 (9.4) 5 (6.4) 0.12 —
Diabetes yes, n (%) — ——— — 0.242
Case 59 (14.8) 29 (13.6) 24 (17.3) 6 (12.8) 0.48 —
Control 34 (8.5) 22 (10.3) 10 (7.2) 2 (4.3) 0.74 —
Obesity yes, n (%) — ——— — 0.852
Case 53 (13.3) 42 (19.6) 10 (7.2) 1 (2.1) 0.000 —
Control 31 (7.8) 17 (7.9) 12 (8.6) 2 (4.3) 0.67 —
Dyslipidemia yes, n (%) — ——— — 0.427
Case 65 (16.3) 39 (18.2) 24 (17.3) 2 (4.3) 0.003 —
Control 39 (9.8) 20 (9.3) 15 (10.8) 4 (8.5) 0.51 —
Table 5: OR (95% CI) of CAD associated to the studied risk factors according to MTHFR C677T polymorphism. OR: odds ratio; 95% CI:
95% conﬁdence interval; CAD: coronary artery disease; MTHFR: methylenetetrahydrofolate reductase; P: signiﬁcant value.
Methylenetetrahydrofolate reductase C677T genotype
677CC P 677CT P 677TT P
Number of subjects 214 — 139 — 47 —
Sex 1.68 (0.97–2.89) 0.063 1.91 (0.97–3.76) 0.062 0.73 (0.21–2.51) 0.615
Smoking habits 4.46 (2.28–8.75) 0.000 4.57 (1.84–11.36) 0.001 0.23 (0.06–0.83) 0.025
Hypertension 1.94 (1.12–3.35) 0.019 2.31 (1.08–4.95) 0.032 2.06 (0.48–8.92) 0.332
Diabetes 1.67 (0.88–3.14) 0.115 2.27 (0.99–5.20) 0.054 1.68 (0.30–9.47) 0.556
Obesity 4.02 (2.10–7.70) 0.000 0.60 (0.24–1.50) 0.275 0.23 (0.02–2.79) 0.251
Dyslipidemia 2.93 (1.56–5.49) 0.001 1.36 (0.64–2.90) 0.422 0.21 (0.03–1.28) 0.091
Hyperhomocysteinaemia 2.47 (1.31–4.65) 0.005 4.31 (2.02–9.19) 0.000 8.68 (2.05–36.69) 0.003
Prospective studies reported conﬂicting results. Some
identiﬁed Hcy as an independent risk factor [18, 19], but
others did not [20, 21]. Recently, Wald et al. [22]p u b -
lished a comprehensive meta-analysis of 16 prospective stud-
ies. Data from 144.936 patients with 3144 combined events
wereanalyzed.TheORfora5μMincreaseHcylevelwas1.23
(95% CI = 1.14–1.32). Zylberstein et al. [23] published the
results of a 24-year follow-up evaluating Hcy quintile, rela-
tive risk was 1.86 (95% CI = 1.06–3.26) for acute myocardial
infarction and 5.14 (95% CI = 2.22–11.92) for death due to
acute myocardial infarction. Our study was of interest be-
cause, despite a high prevalence of coronary morbidity and
mortality in Morocco [24], the total cholesterol concentra-
tions are relatively low and are not the major cause for the
development of atherosclerosis. In the light of these ﬁndings,
wethoughtthatplasmatHcyconcentrationsmightbeanim-
portant risk factor for CAD in Morocco. In fact, we found
that plasma tHcy concentrations above 15μmol/L were a sig-
niﬁcant and independent risk factor for CAD [25, 26]. This
association was persistent in men and women when they were
considered separately.
The role of environmental factors in determining tHcy
levels was examined ﬁrst. Cigarette smoking is known to in-
crease plasma homocysteine [27]. Our results conﬁrmed this
eﬀect which suggests that smoking increases HHcy, which in
turn increases risk of CAD. Several mechanisms might ex-
plain the increased risk in smokers with high plasma tHcy.
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Table 6: Cardiovascular risk factors that are having a signiﬁcant eﬀect on CAD. Logistic regression model with backward likelihood ratio
method. B: the logistic regression coeﬃcient; SE: standard error; Wald: statistic value of Wald; Df: degree of freedom; Sig.: signiﬁcant value;
Exp(B): exponential of B; 95% CI: 95% conﬁdence interval.
Variable B SE Wald Df Sig. Exp(B) 95% CI for Exp(B)
Lower Upper
Smoking 1.28 0.39 11.00 1 0.001 3.61 1.69 7.72
Hypertension 1.13 0.25 19.84 1 0.000 3.09 1.88 5.08
Diabetes 0.92 0.28 10.65 1 0.001 2.50 1.44 4.34
Dyslipidemia 1.38 0.32 18.27 1 0.000 3.99 2.12 7.53
Hyperhomocysteinaemia 1.07 0.41 6.93 1 0.009 2.93 1.32 6.51
MTHFR C677T∗ Smoking — — 14.47 2 0.001 — — —
MTHFR 677CT∗ Smoking 0.02 0.62 0.00 1 0.979 1.02 0.30 3.44
MTHFR 677TT∗ Smoking −4.45 1.19 13.92 1 0.000 0.01 0.00 0.12
Dyslipidemia∗ Hyperhomocysteinaemia −1.95 0.56 11.95 1 0.001 0.14 0.05 0.43
Hyperhomocysteinaemia∗ MTHFR C677T 12.10 2 0.002 — — — — —
Hyperhomocysteinaemia∗ MTHFR 677CT 1.07 0.52 4.30 1 0.038 2.92 1.06 8.06
Hyperhomocysteinaemia∗ MTHFR 677TT 3.55 1.12 10.14 1 0.002 34.96 3.92 311.69
Constant −1.62 0.24 47.01 1 0.000 — — —
∗The between variables interactive eﬀects.
peroxidation, enhanced tissue factor activation, and reduced
Von Willebrand factor, via several diﬀerent interactive mech-
anisms [28, 29]. Nicotine and carbon monoxide separately
producetachycardia,hypertension,andvasoconstrictionand
both produce direct endothelial damage [30]. Smoking also
aﬀects vaso-occlusive factors such as platelet aggregation,
plasma viscosity, and ﬁbrinogen levels [31, 32]. The mech-
anism by which mild HHcy is atherogenic is still not com-
pletely understood. Homocysteine may damage endothelial
cells and has been shown to be associated with elevated lev-
els of von-Willebrand factor in vivo [33], and with enhanced
nitric oxide production in cultured cells [34], and thus would
increase risk of atherosclerosis. Also, Woo et al. [35]d e m o n -
strated impaired ﬂow-mediated dilatation of the brachial
artery in 17 healthy individuals who had no other risk fac-
tor except HHcy. Furthermore, tHcy levels and endothelial
function were corrected with folic acid supplementation. In
addition, some studies have demonstrated an association be-
tween homocysteine and an increase risk of initial and recur-
rent venous thrombosis [36], and although this has not been
shown in all studies [37], it has been conﬁrmed in a meta-
analysis in patients with fasting HHcy [38].
Several characteristics of the present study deserve to be
stressed. First, as in previous studies [39], we found a strong
link between the MTHFR gene C677T polymorphism and
plasmatHcylevels.Second,ourstudyprovidesaveryreliable
phenotypecharacterizationofCAD,byperformingcoronary
angiography in all patients and controls. Third, our study is
the ﬁrst and the largest one conducted in Moroccan pop-
ulation, this facilitates the examination of the thermolabile
MTHFRgenotypeasanindependentriskfactorforCADand
of the relations between genotypes, tHcy, and risk.
Inthepresentstudy,MTHFRgeneC677Tpolymorphism
was signiﬁcantly associated with CAD (P<. 05). Com-
pared with homozygous wild-type, the homozygous mutant
of MTHFR gene was associated to a signiﬁcant CAD risk in-
crease. It is in the same line with Frosst et al. [11]. In par-
ticular, Morita et al. [40] reported that the frequency of this
mutation was correlated with the severity of stenotic lesions
and the number of stenotic coronary arteries, suggesting that
this mutation is closely associated with the severity of CAD.
Therefore, the ﬁnding of an increased risk of CAD associated
with MTHFR is not surprising because MTHFR is strongly
associated with an increased risk of HHcy.
In the original description of thermolabile MTHFR, Sel-
hub and D’Angelo et al. [17] reported that thermolabile
MTHFR, which is correlated with the 677TT genotype, can
be an inherited risk factor for CAD. They documented a
prevalence of 17% in patients with CAD and of 5% in con-
trol subjects. van der Put et al. [5] reported decreased plasma
folate concentrations in individuals homozygous for the mu-
tation.
In contrast with our study, Anderson et al. [41], in a
prospective study of patients with angiographically proved
CAD, found no relation between MTHFR gene C677T poly-
morphism and the risk of CAD. In a health report of US
physicians, the frequency of the MTHFR genotypes was sim-
ilar between patients and control subjects [42]. The discrep-
ancy between the results from all those studies is unclear
and may be due to diﬀerences in nutritional intake of co-
f a c t o r sr e q u i r e df o rt h eM T H F Rp a t h w a y ,s u c ha sv i t a m i n
B12 or folate, or other ethnic diﬀerences (e.g., weight, BMI)
[43].
Our study showed a positive association between the ho-
mozygous mutant genotype and elevated plasma tHcy levels
in both cases and controls. Similar ﬁndings were observed
in the NHLBI Family Heart Study [10]. This association
suggests that MTHFR gene C677T mutation may increase
plasma tHcy levels and could be an independent predictor of
plasma homocysteine levels, particularly in the setting of low
folate status. On this basis, but without implying causality, it
is reasonable to suggest that the eﬀect of the 677TT genotype8 Journal of Biomedicine and Biotechnology
onCADmaybemediatedthroughhighplasmatHcyandlow
plasma folate concentration.
Therefore,itis important to note thatwhenCAD andsex
categories were considered together, MTHFR C677T poly-
morphism was not associated to CAD (P>. 05) in men; but
in women this relation was at the limit of the signiﬁcance
(P = .049). Our data do not allow us to conclude clearly
about MTHFR C677T mutation and CAD association ac-
cording to sex diﬀerences.
When we assess the distribution of conventional cardio-
vascular risk factors according to MTHFR C677T polymor-
phism,wefoundthathomozygous677TTwithCADhadsig-
niﬁcantly lower frequencies of these risk factors than those
having677CTand677CC.In677CCand677CTsubjects,the
CAD risk is mediated by traditional risk factors and HHcy,
while in 677TT subjects, the CAD risk is conferred only by
isolated HHcy.
5. CONCLUSION
In the studied Moroccan population, elevated tHcy level is a
strong risk factor for CAD independently of the traditional
risk factors, and this CAD risk increase is strongly inﬂuenced
by MTHFR C677T polymorphism. The MTHFR and smok-
inghabitsarethemajorcausesofHHcy.Thereisasigniﬁcant
interactive eﬀect of MTHFR polymorphism and HHcy on
CAD. Traditional risk factors were associated to a signiﬁcant
increased risk of CAD in subjects with 677CT and 677CC
genotypes, while HHcy were the main and sole risk factor of
CAD in subjects with 677TT. For an eventual strategy of car-
diovascular disease prevention in Morocco, it is obvious that
conventional cardiovascular risk factors should be viewed in
the context of MTHFR genotype and, of course, of other ge-
netic determinants.
REFERENCES
[1] A. J. Lusis, R. Mar, and P. Pajukanta, “Genetics of atheroscle-
rosis,” Annual Review of Genomics and Human Genetics, vol. 5,
pp. 189–218, 2004.
[2] R. A. Hegele and R. L. Pollex, “Genetic and physiological
insights into the metabolic syndrome,” American Journal of
Physiology—Regulatory Integrative and Comparative Physiol-
ogy, vol. 289, no. 3, pp. R663–R669, 2005.
[3] J. Geisel, I. Zimbelmann, H. Schorr, et al., “Genetic defects
as important factors for moderate hyperhomocysteinemia,”
Clinical Chemistry and Laboratory Medicine,v o l .3 9 ,n o .8 ,p p .
698–704, 2001.
[ 4 ] C .J .B o u s h e y ,S .A .A .B e r e s f o r d ,G .S .O m e n n ,a n dA .G .M o -
tulsky,“Aquantitativeassessmentofplasmahomocysteineasa
risk factor for vascular disease: probable beneﬁts of increasing
folic acid intakes,” Journal of the AmericanMedical Association,
vol. 274, no. 13, pp. 1049–1057, 1995.
[ 5 ]N .M .J .v a nd e rP u t ,R .P .M .S t e e g e r s - T h e u n i s s e n ,P .F r o s s t ,
et al., “Mutated methylenetetrahydrofolate reductase as a risk
factor for spina biﬁda,” The Lancet, vol. 346, no. 8982, pp.
1070–1071, 1995.
[6] S.-S. Kang and P. W. K. Wong, “Genetic and nongenetic fac-
tors for moderate hyperhomocyst(e)inemia,” Atherosclerosis,
vol. 119, no. 2, pp. 135–138, 1996.
[7] S.-S. Kang, P. W. K. Wong, A. Susmano, J. Sora, M. Norusis,
and N. Ruggie, “Thermolabile methylenetetrahydrofolate re-
ductase: an inherited risk factor for coronary artery disease,”
American Journal of Human Genetics, vol. 48, no. 3, pp. 536–
545, 1991.
[8] S.-S.Kang,E.L.P assen,N.R uggie,P .W .K.W ong,andH.Sora,
“Thermolabile defect of methylenetetrahydrofolate reductase
in coronary artery disease,” Circulation, vol. 88, no. 4 part 1,
pp. 1463–1469, 1993.
[ 9 ]A .M .T .E n g b e r s e n ,D .G .F r a n k e n ,G .H .J .B o e r s ,E .M .B .
Stevens, F. J. M. Trijbels, and H. J. Blom, “Thermolabile 5,10-
methylenetetrahydrofolate reductase as a cause of mild hy-
perhomocysteinemia,” American Journal of Human Genetics,
vol. 56, no. 1, pp. 142–150, 1995.
[10] P. F. Jacques, A. G. Bostom, R. R. Williams, et al., “Relation
between folate status, a common mutation in methylenete-
trahydrofolate reductase, and plasma homocysteine concen-
trations,” Circulation, vol. 93, no. 1, pp. 7–9, 1996.
[11] P. Frosst, H. J. Blom, R. Milos, et al., “A candidate genetic
riskfactorforvasculardisease:acommonmutationinmethyl-
enetetrahydrofolate reductase,” Nature Genetics, vol. 10, no. 1,
pp. 111–113, 1995.
[12] L. A. J. Kluijtmans, L. P. W. J. van den Heuvel, G. H. J. Boers,
et al., “Molecular genetic analysis inmild hyperhomocysteine-
mia:acommonmutationinthemethylenetetrahydrofolatere-
ductasegene isageneticriskfactor forcardiovascular disease,”
American Journal of Human Genetics, vol. 58, no. 1, pp. 35–41,
1996.
[13] F. Frantzen, A. L. Faaren, I. Alfheim, and A. K. Nordhei, “En-
zyme conversion immunoassay for determining total homo-
cysteineinplasmaorserum,”ClinicalChemistry,vol.44,no.2,
pp. 311–316, 1998.
[14] A. Laraqui, N. Bennouar, F. Meggouh, et al., “Homocysteine,
lipoprotein (a): risk factors for coronary heart disease,” An-
nales de Biologie Clinique, vol. 60, no. 5, pp. 549–557, 2002.
[15] W. G. Christen, U. A. Ajani, R. J. Glynn, and C. H. Hen-
nekens, “Blood levels of homocysteine and increased risks of
cardiovascular disease: causal or casual?” Archives of Internal
Medicine, vol. 160, no. 4, pp. 422–434, 2000.
[16] K. S. McCully, “Homocysteine and vascular disease,” Nature
Medicine, vol. 2, no. 4, pp. 386–389, 1996.
[17] J. Selhub and A. D’Angelo, “Hyperhomocysteinemia and
thrombosis: acquired conditions,” Thrombosis and Haemosta-
sis, vol. 78, no. 1, pp. 527–531, 1997.
[18] M. J. Stampfer, M. R. Malinow, W. C. Willett, et al., “A
prospective study of plasma homocyst(e)ine and risk of my-
ocardial infarction in US physicians,” Journal of the American
Medical Association, vol. 268, no. 7, pp. 877–881, 1992.
[19] E. Arnesen, H. Refsum, K. H. Bonaa, P. M. Ueland, O. H.
Forde, and J. E. Nordrehaug, “Serum total homocysteine and
coronary heart disease,” International Journal of Epidemiology,
vol. 24, no. 4, pp. 704–709, 1995.
[ 2 0 ]R .W .E v a n s ,B .J .S h a t e n ,J .D .H e m p e l ,J .A .C u t l e r ,a n dL .
H. Kuller, “Homocyst(e)ine and risk of cardiovascular disease
in the multiple risk factor intervention trial,” Arteriosclerosis,
Thrombosis, and Vascular Biology, vol. 17, no. 10, pp. 1947–
1953, 1997.
[ 2 1 ]A .R .F o l s o m ,F .J .N i e t o ,P .G .M c G o v e r n ,e ta l . ,“ P r o s p e c t i v e
study of coronary heart disease incidence in relation to fasting
total homocysteine, related genetic polymorphisms, and B vi-
tamins:theatherosclerosisriskincommunities(ARIC)study,”
Circulation, vol. 98, no. 3, pp. 204–210, 1998.Nawal Bennouar et al. 9
[22] D. S. Wald, M. Law, and J. K. Morris, “Homocysteine and
cardiovascular disease: evidence on causality from a meta-
analysis,” British Medical Journal, vol. 325, no. 7374, pp. 1202–
1206, 2002.
[23] D. E. Zylberstein, C. Bengtsson, C. Bj¨ orkelund, et al., “Serum
homocysteine in relation to mortality and morbidity from
coronary heart disease: a 24-year follow-up of the population
study of women in gothenburg,” Circulation, vol. 109, no. 5,
pp. 601–606, 2004.
[24] M. A. Tazi, S. Abir-Khalil, N. Chaouki, et al., “Prevalence of
the main cardiovascular risk factors in Morocco: results of a
national survey, 2000,” Journal of Hypertension, vol. 21, no. 5,
pp. 897–903, 2003.
[25] L. M. Graham, L. E. Daly, H. M. Refsum, et al., “Plasma ho-
mocysteine as a risk factor for vascular disease: The European
ConcertedActionProject,”JournaloftheAmericanMedicalAs-
sociation, vol. 277, no. 22, pp. 1775–1781, 1997.
[26] S. L. Tokg¨ ozoˇ glu, M. Alikas ¸ifoˇ glu, I. ¨ Unsal, et al., “Methylene
tetrahydrofolate reductase genotype and the risk and extent
of coronary artery disease in a population with low plasma
folate,” Heart, vol. 81, no. 5, pp. 518–522, 1999.
[ 2 7 ]O .N y g a r d ,S .E .V o l l s e t ,H .R e f s u m ,e ta l . ,“ T o t a lp l a s m ah o -
mocysteine and cardiovascular risk proﬁle: the Hordaland ho-
mocysteine study,” Journal of the American Medical Associa-
tion, vol. 274, no. 19, pp. 1526–1533, 1995.
[ 2 8 ]C .E .B a r t e c c h i ,T .D .M a c K e n z i e ,a n dR .W .S c h r i e r ,“ T h e
human costs of tobacco use (1),” New England Journal of
Medicine, vol. 330, no. 13, pp. 907–912, 1994.
[ 2 9 ]T .D .M a c K e n z i e ,C .E .B a r t e c c h i ,a n dR .W .S c h r i e r ,“ T h e
human costs of tobacco use (2),” New England Journal of
Medicine, vol. 330, no. 14, pp. 975–980, 1994.
[30] R. H. Fryer, B. D. Wilson, D. B. Gubler, L. A. Fitzgerald, and
G. M. Rodgers, “Homocysteine, a risk factor for premature
vascular disease and thrombosis, induces tissue factor activity
in endothelial cells,” Arteriosclerosis and Thrombosis, vol. 13,
no. 9, pp. 1327–1333, 1993.
[31] L. A. Harker, R. Ross, S. J. Slichter, and C. R. Scott, “Homocys-
tineinducedarteriosclerosis.Theroleofendothelialcellinjury
and platelet response in its genesis,” Journal of Clinical Investi-
gation, vol. 58, no. 3, pp. 731–741, 1976.
[32] F. Nappo, N. de Rosa, R. Marfella, et al., “Impairment of en-
dothelial functions by acute hyperhomocysteinemia and re-
versal by antioxidant vitamins,” Journal of the American Medi-
cal Association, vol. 281, no. 22, pp. 2113–2118, 1999.
[ 3 3 ] S .C .d eJ o n g ,C .D .A .S t e h o u w e r ,M .v a nd e nB e r g ,U .M .V i s -
cher, J. A. Rauwerda, and J. J. Emeis, “Endothelial marker pro-
teinsinhyperhomocysteinemia,”ThrombosisandHaemostasis,
vol. 78, no. 5, pp. 1332–1337, 1997.
[34] G. R. Upchurch Jr., G. N. Welch, A. J. Fabian, A. Pigazzi, J. F.
Keaney Jr., and J. Loscalzo, “Stimulation of endothelial nitric
oxideproductionbyhomocyst(e)ine,”Atherosclerosis,vol.132,
no. 2, pp. 177–185, 1997.
[35] K. S. Woo, P. Chook, Y. I. Lolin, J. E. Sanderson, C. Metreweli,
and D. S. Celermajer, “Folic acid improves arterial endothelial
function in adults with hyperhomocystinemia,” Journal of the
American College of Cardiology, vol. 34, no. 7, pp. 2002–2006,
1999.
[36] C. Legnani, G. Palareti, F. Grauso, et al., “Hyperhomo-
cyst(e)inemia and a common methylenetetrahydrofolate re-
ductase mutation (Ala
223Val MTHFR) in patients with in-
herited thrombophilic coagulation defects,” Arteriosclerosis,
Thrombosis, and Vascular Biology, vol. 17, no. 11, pp. 2924–
2929, 1997.
[37] P. M. Ridker, C. H. Hennekens, J. Selhub, J. P. Miletich, M.
R. Malinow, and M. J. Stampfer, “Interrelation of hyperho-
mocyst(e)inemia, factor V Leiden, and risk of future venous
thromboembolism,”Circulation,vol.95,no.7,pp.1777–1782,
1997.
[38] J. G. Ray, “Meta-analysis of hyperhomocysteinemia as a risk
factor for venous thromboembolic disease,” Archives of Inter-
nal Medicine, vol. 158, no. 19, pp. 2101–2106, 1998.
[39] L. Brattstr¨ o m ,D .E .L .W i l c k e n ,J .¨ Ohrvik, and L. Brudin,
“Common methylenetetrahydrofolate reductase gene muta-
tion leads to hyperhomocysteinemia but not to vascular dis-
ease: the result of a meta- analysis,” Circulation, vol. 98, no. 23,
pp. 2520–2526, 1998.
[40] H.Morita,J.-I.Taguchi,H.Kurihara,etal.,“Geneticpolymor-
phismof5,10-methylenetetrahydrofolatereductase(MTHFR)
asariskfactorforcoronaryarterydisease,”Circulation,vol.95,
no. 8, pp. 2032–2036, 1997.
[ 4 1 ]J .L .A n d e r s o n ,G .J .K i n g ,M .J .T h o m s o n ,e ta l . ,“ Am u t a t i o n
in the methylenetetrahydrofolate reductase gene is not associ-
atedwithincreasedriskforcoronaryarterydiseaseormyocar-
dial infarction,” Journal of the American College of Cardiology,
vol. 30, no. 5, pp. 1206–1211, 1997.
[42] J. Ma, M. J. Stampfer, C. H. Hennekens, et al., “Methylenete-
trahydrofolatereductasepolymorphism,plasmafolate,homo-
cysteine, and risk of myocardial infarction in US physicians,”
Circulation, vol. 94, no. 10, pp. 2410–2416, 1996.
[43] E. S. Brilakis, P. B. Berger, K. V. Ballman, and R. Rozen,
“Methylenetetrahydrofolate reductase (MTHFR) 677C→ T
and methionine synthase reductase (MTRR) 66A→ Gp o l y -
morphisms: association with serum homocysteine and angio-
graphic coronary artery disease in the era of ﬂour products
fortiﬁed with folic acid,” Atherosclerosis, vol. 168, no. 2, pp.
315–322, 2003.